Logo
Subscribe Now

All Posts by Date

Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease

Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease

Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries

Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis

LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis

Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China

Image

Stay Connected

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2021 PharmaShots - All Rights Reserved.